CTOs on the Move

Genentech

www.genetech.com

 
Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009.
  • Number of Employees: 5K-10K
  • Annual Revenue: $0-1 Million
  • www.genetech.com
  • 1, DNA Way
    South San Francisco, CA USA 94080
  • Phone: 650.225.1000

Executives

Name Title Contact Details

Similar Companies

Strata Oncology

Strata Oncology, Inc. is a precision oncology company dedicated to delivering the best possible treatment for each patient with cancer. The company combines molecular profiling, real-world data, and a large-scale clinical trial platform to identify and deliver optimal treatments for patients with cancer.

MedWorxs

MedWorxs is a Evergreen, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BiPar Sciences

BiPar Sciences Incorporated is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tonix Pharmaceuticals

Tonix Pharmaceuticals develops first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix`s lead product candidate, TNX-102 SLAttribution (cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic stress disorder (PTSD). Product candidate TNX-201Attribution ((R)-isometheptene mucate) is in development for episodic tension-type headache, the most common form of headache.

IO Biotech

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.